Drug Type Small molecule drug |
Synonyms Atorvastatin/BR-A 657, Fimasartan/atorvastatin |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (14 Sep 2021), |
Regulation- |
Molecular FormulaC66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS Registry344423-98-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyslipidemias | KR | 23 Sep 2021 | |
Hypertension | KR | 14 Sep 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyslipidemias | Phase 3 | - | - | |
Hypertension | Phase 3 | - | - | |
Hyperlipidemias | Preclinical | KR | 23 Dec 2016 |